Disease · MONDO_0043771

radiodermatitis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. radiodermatitis. Diseases, record MONDO_0043771. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0043771

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: radiodermatitis; Open Targets
Open Targets ID: MONDO_0043771; Open Targets
Other names: dermatitis radiation, radiation dermatitis, radiation-induced dermatitis; Open Targets
MeSH: D011855; MeSH
NCI Thesaurus: C3349; NCI Thesaurus
Highest stage of its drugs: Phase 2, for 1 of its 12 drugs, from ClinicalTrials.gov; Open Targets

Drugs12

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
TROLAMINE	CHEMBL446061	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
LUT-014	CHEMBL5095249	Small molecule	Phase 1/2	ClinicalTrials.gov	1	1	1	Drugs and targets
SINECATECHINS	CHEMBL1201723		Phase 1/2	ClinicalTrials.gov	1	1	0	Drugs and targets
COLCHICINE	CHEMBL107	Small molecule	Phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets
FLUOROURACIL	CHEMBL185	Small molecule	Phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets
MITOMYCIN	CHEMBL105	Small molecule	Phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets
SAPROPTERIN	CHEMBL1201774	Small molecule	Phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets
TEMPOL	CHEMBL607023	Small molecule	Phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets
ALOE	CHEMBL2108221		Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets
HONEY	CHEMBL2108391		Unknown	ClinicalTrials.gov	1	1	0	Drugs and targets

1 to 10 of 12

See all 12 drugs

Targets17

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
PAH	Phenylalanine-4-hydroxylase	1	Phenylalanine-4-hydroxylase activator	Phase 1	https://conductscience.org/library/genes/5053	Drugs and targets
TUBA1A	Tubulin	1	Tubulin inhibitor	Phase 1	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	1	Tubulin inhibitor	Phase 1	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	1	Tubulin inhibitor	Phase 1	https://conductscience.org/library/genes/84790	Drugs and targets
TUBA3C	Tubulin	1	Tubulin inhibitor	Phase 1	https://conductscience.org/library/genes/7278	Drugs and targets
TUBA3E	Tubulin	1	Tubulin inhibitor	Phase 1	https://conductscience.org/library/genes/112714	Drugs and targets
TUBA4A	Tubulin	1	Tubulin inhibitor	Phase 1	https://conductscience.org/library/genes/7277	Drugs and targets
TUBB	Tubulin	1	Tubulin inhibitor	Phase 1	https://conductscience.org/library/genes/203068	Drugs and targets
TUBB1	Tubulin	1	Tubulin inhibitor	Phase 1	https://conductscience.org/library/genes/81027	Drugs and targets
TUBB2A	Tubulin	1	Tubulin inhibitor	Phase 1	https://conductscience.org/library/genes/7280	Drugs and targets

1 to 10 of 17

See all 17 targets

Trials7

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 3 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02165605	HylaCare in the Treatment of Acute Skin Changes in Patients Undergoing Radiotherapy for Breast Cancer	Not applicable	28	2020-10-22	Breast Cancer	HYALURONIC ACID	Its record names the disease	ClinicalTrials.gov
NCT01324141	Topical MTS-01 for Dermatitis During Radiation and Chemotherapy for Anal Cancer	Phase 1	6	2021-11-23	Anal Cancer	FLUOROURACIL, MITOMYCIN, TEMPOL	Its record names the disease	ClinicalTrials.gov
NCT02729324	Comparison of Efficacy and Safety Between Medical Radiation Protectants (FORRAD®) and Trolamine (Biafine) for the Management of Radiation Dermatitis in Patients With Nasopharyngeal Carcinoma Receiving IMRT	Phase 2	136		Nasopharyngeal Neoplasms, Radiodermatitis	TROLAMINE	Its record names the disease	ClinicalTrials.gov
NCT04116151	Effectiveness of a Cream for Treatment of Dermatitis in Patients Whith Breast Cancer	Not applicable	78		DERMATITIS INDUCED BY RADIOTHERAPY IN PATIENTS WHITH BREAST CANCER	ALOE	Its record names the disease	ClinicalTrials.gov
NCT05335148	Study to Evaluate the Safety of Colchicine	Phase 1	30		Radiation Therapy	COLCHICINE	Its record names the disease	ClinicalTrials.gov
NCT04261387	LUT014 for the Treatment of Radiation Induced Dermatitis in Breast Cancer Patients	Phase 1/2	28		Radiation Dermatitis	LUT-014	Its record names the disease	ClinicalTrials.gov
NCT05299203	BH4 in the Prevention and Treatment of Radiation-induced Skin Reactions for Head and Neck Squamous Cell Carcinoma (Including Nasopharyngeal Carcinoma)	Phase 1	18		Head and Neck Squamous Cell Carcinoma	SAPROPTERIN	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials2

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
38273379	DERIVED	1	PubMed
31273506	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0043771

GET https://conductscience.org/api/diseases/v1/MONDO_0043771/drugs

API reference For AI assistants